Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | USP10 | Q14694 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | PKM | P14618 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | CRHBP | P24387 | 1/20 | 0.50 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.50 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.49 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.47 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.47 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.47 |
| ▸ | FLT1 | P17948 | 1/20 | 0.47 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.47 |
| ▸ | KDR | P35968 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18703780 | 0.82 | KDM4E (0.48) | KMT2AALDH1A1MAPTLMNAKDM4E | |
| SCHEMBL559830 | 0.82 | VCAM1 (0.64) | KMT2AALDH1A1MAPTPKMLMNA | |
| SCHEMBL30525281 | 0.82 | VCAM1 (0.64) | KMT2AALDH1A1MAPTPKMLMNA | |
| SCHEMBL6422578 | 0.81 | KMT2A (0.65) | KMT2AUSP10ALDH1A1MAPTRAB9A | |
| Methane SCHEMBL27578247 | 0.81 | VCAM1 (0.62) | KMT2AALDH1A1MAPTPKMLMNA | |
| SCHEMBL161836 | 0.79 | CASP6 (0.60) | KMT2AALDH1A1MAPTLMNAVCAM1 | |
| SCHEMBL2388784 | 0.79 | VCAM1 (0.54) | KMT2AALDH1A1MAPTLMNAPOLB | |
| SCHEMBL16960905 | 0.79 | VCAM1 (0.54) | KMT2AALDH1A1MAPTLMNAPOLB | |
| SCHEMBL12933644 | 0.79 | LMNA (0.55) | KMT2AALDH1A1MAPTRAB9APKM | |
| SCHEMBL25200200 | 0.79 | KDM4E (0.45) | KMT2AALDH1A1MAPTNPC1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130296332-A1 | 1H-QUINAZOLINE-2,4-DIONES | NOVARTIS AG (CH) | 2013-11-07 | — | — | US | disclosed |
| US-20130296332-A1 | 1H-QUINAZOLINE-2,4-DIONES | NOVARTIS AG (CH) | 2013-11-07 | — | — | US | disclosed |
| US-8513268-B2 | 1H-quinazoline-2,4-diones processes for their production, pharmaceutical compositions, and treatment for epilepsy | NOVARTIS AG (CH) | 2013-08-20 | — | — | US | disclosed |
| US-8513268-B2 | 1H-quinazoline-2,4-diones processes for their production, pharmaceutical compositions, and treatment for epilepsy | NOVARTIS AG (CH) | 2013-08-20 | — | — | US | disclosed |
| EP-2476671-A1 | 1H-Quinazoline-2,4-diones | Novartis AG (CH) | 2012-07-18 | — | — | EP | disclosed |
| EP-2468732-A1 | 1H-Quinazoline-2,4-diones | Novartis AG (CH) | 2012-06-27 | — | — | EP | disclosed |
| EP-2463278-A1 | 1H-QUINAZ0LINE-2,4-DIONES AND THEIR USE AS AMPA-RECEPTOR LIGANDS | Novartis AG (CH) | 2012-06-13 | — | — | EP | disclosed |
| US-20110294818-A1 | 1H-QUINAZOLINE-2,4-DIONES | NOVARTIS AG | 2011-12-01 | — | — | US | disclosed |
| US-8012988-B2 | N-(2,4-dioxo-6-(tetrahydrofuran-2-yl)-7-(trifluoromethyl)-1,4-dihydro-2H-quinazolin-3-yl)methanesulfonamide | NOVARTIS AG (CH) | 2011-09-06 | — | — | US | disclosed |
| US-20100144747-A1 | 1H-QUINAZ0LINE-2,4-DIONES | NOVARTIS AG | 2010-06-10 | — | — | US | disclosed |
| US-7655666-B2 | Substituted 1H-quinazoline-2,4-diones useful as AMPA receptor ligands | NOVARTIS AG (CH) | 2010-02-02 | — | — | US | disclosed |
| US-20080153836-A1 | N-(2,4-Dioxo-1,4-dihydro-2H-quinazolin-3-yl)-methanesulfonamide derivatives; condensation, cyclization, reduction; AMPA (A-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor antagonists; schizophrenia, bipolar disorders, Parkinson's Disease, antiepileptic agents; psychological disorders | NOVARTIS AG (CH) | 2008-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294818-A1 | 1H-QUINAZOLINE-2,4-DIONES | CYP1A2, QDPR, CYP3A7 | KMT2A 1922/4885USP10 4293/4885ALDH1A1 115/4885 |
| US-20100144747-A1 | 1H-QUINAZ0LINE-2,4-DIONES | CYP3A7, CYP1A2, UGT1A7 | KMT2A 1186/4885USP10 2052/4885ALDH1A1 143/4885 |
| US-20080153836-A1 | N-(2,4-Dioxo-1,4-dihydro-2H-quinazolin-3-yl)-methanesulfonamide derivatives; condensation, cyclization, reduction; AMPA (A-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor antagonists; schizophrenia, bipolar disorders, Parkinson's Disease, antiepileptic agents; psychological disorders | GRIN2A, GRIN1, GRIN2D | KMT2A 1588/4885USP10 4187/4885ALDH1A1 804/4885 |
| US-20130296332-A1 | 1H-QUINAZOLINE-2,4-DIONES | CYP1A2, QDPR, CYP3A7 | KMT2A 1922/4885USP10 4293/4885ALDH1A1 115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.